CD19 and ovarian cancer: CIML NK cells can also be genetically modified with chimeric antigen receptors (CARs), which exhibit greater functional activity than conventional CAR NK cells.24 Studies have shown that CD19-CAR CIML NK cells exhibit stronger cytotoxic activity against NK-resistant lymphoma cell lines than do CD19-CAR NK cells in vitro.24 Tarannum M’s team reported that CAR CIML NK cells targeting MSLN showed promising activity in ovarian cancer.23